Kevin Chow

Dr. Chow serves as an Operating Partner of Accelerator and Chief Business Officer of ALSP Orchid Acquisition Corporation I (NASDAQ: ALORU | ALOR). Concurrently he serves as President of Incisive Genetics. Dr. Chow was most recently Co-founder, President and CEO of Vitaeris, a privately held biotechnology company conducting a multinational Phase 3 study in kidney transplant rejection (acquired by CSL Behring). Prior to co-founding Vitaeris in early 2016, Dr. Chow served as Head of Business Development at Alder Biopharmaceuticals, where he led partnering efforts for Alder’s monoclonal antibody pipeline. Previously, Dr. Chow led pulmonary in- licensing at Gilead Sciences and helped manage the integration of Corus Pharma after its acquisition by Gilead in 2006. Prior to Gilead, Dr. Chow served as Director of Business Development for Corus Pharma, a specialty pharmaceutical company focused on cystic fibrosis and asthma drug development. From 2000-2003 Dr. Chow served in various business development roles with Diversa.

Dr. Chow received his B.Sc., M.Sc., and Ph.D. degrees in ​Microbiology and Immunology from the University of British Columbia in Vancouver, Canada.